Request for Information - Next-Generation COVID-19 Vaccines
Looking for contract opportunity help?
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
General Information
- Contract Opportunity Type: Sources Sought (Updated)
- Updated Published Date: Apr 24, 2023 04:25 pm EDT
- Original Published Date:
- Requirements Strategy:
- Inactive Policy: 15 days after response date
- Updated Inactive Date:
- Original Inactive Date:
- Initiative:
- None
Classification
- Original Set Aside:
- Product Service Code:
- NAICS Code:
- Place of Performance:
Description
The Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), is issuing this Request for Information (RFI) to collect feedback from current and potential biopharmaceutical partners. Information collected from this RFI will serve as continued market research for possible future programs where BARDA would partner with the National Institutes of Allergy and Infectious Diseases (NIAID) as well as other organizations to achieve the pandemic preparedness goals set forth by the U.S. Government (USG).
BARDA is issuing this RFI to assist in understanding the advanced developmental landscape of next-generation COVID-19 vaccines. For the purpose of this RFI, next generation vaccines include those with enhanced breadth of protection to variants, improved durability, and those with an enhanced ability to block infection/transmission including mucosal vaccines, relative to currently approved vaccines. BARDA is particularly interested in novel vaccine candidates in clinical trials or capable of entering clinical trials within 9 months.
Contact Information
Primary Point of Contact
- Richard Hall
- Richard.Hall@hhs.gov
Secondary Point of Contact
- Jonathan Gonzalez
- Jonathan.Gonzalez@hhs.gov